Core Viewpoint - The company demonstrates strong confidence in its business operations, particularly in the fields of narcotic drugs and elderly care services, as discussed during a recent offline research meeting with institutional investors. Group 1: Narcotic Drug Development - The company has established a comprehensive product cluster in the narcotic pain relief sector, with a focus on the oxycodone series, which includes both raw materials and formulations [2] - The company is the only domestic pharmaceutical enterprise with an integrated advantage in oxycodone raw material and formulation, supported by 100% self-supply of raw materials and strong cost control [2] - The company disclosed that its oxycodone sustained-release tablets are in the registration review stage, with expected approvals in Q4 2026 for the 40mg version and Q3 2027 for the 10mg version [3] - The company emphasizes a unique self-operated model for promoting oxycodone sustained-release tablets, focusing on academic-driven strategies and digital penetration to enhance market coverage [3] - In the ADHD medication sector, the company utilizes a resin-controlled release microsphere technology to improve dosing precision and enhance efficacy and safety for children [3] Group 2: Elderly Care Business Optimization - The company has made significant progress in optimizing its elderly care business model, focusing on cost reduction and efficiency improvements [4] - The Nalan Garden elderly care project has implemented a three-dimensional pricing model to enhance profit contributions per bed while improving service quality and client structure [4] - The company plans to maintain high occupancy rates in community elderly care services while refining management and service quality [4] - The Taihe Ruiyuan project will launch a "trial stay experience" initiative to address the challenges of high turnover rates among elderly residents, enhancing brand promotion and occupancy conversion [5] - The company aims to adapt to changes in centralized procurement policies by focusing on differentiated products and comprehensive value competition strategies [5]

Group 1: Biopharmaceutical Segment - The biopharmaceutical segment accounts for over 80% of the company's revenue, with the strategic product, hydromorphone injection, showing continuous growth. The company aims to establish the most comprehensive hydromorphone product cluster in China, with several products in the pipeline [1][2]. - The approval timelines for hydromorphone sustained-release tablets (10mg and 40mg) are expected in Q4 2026 and Q3 2027, respectively, while acetaminophen-hydromorphone tablets are anticipated to be approved by Q2 2028 [2]. Group 2: Market Strategies - The marketing strategy for hydromorphone sustained-release tablets focuses on a self-operated model, academic-driven promotion, optimized access, tiered channel strategies, digital penetration, and compliance risk control to enhance market share and coverage [2][4]. - The acetaminophen-hydromorphone tablet market is projected to reach CNY 350-400 million by 2025, with a growth rate of approximately 20%-30%. Public healthcare accounts for over 95% of sales, with limited retail and private hospital contributions [2][3]. Group 3: Elderly Care Business - The company has implemented cost-reduction and efficiency-enhancing measures in its elderly care business, with initial positive results. Key strategies include a three-dimensional pricing model and personalized service systems to improve service value and stabilize occupancy rates [5][6]. - The company plans to maintain high occupancy rates in community projects while enhancing management and service quality. The focus will be on personalized care and service systems to boost customer satisfaction and revenue per bed [7][8]. Group 4: ADHD Medication Development - The core technological barrier for the ADHD medication methylphenidate series is the "resin-controlled release microsphere technology," which allows for precise dosage adjustments and stable drug release over 12 hours, significantly improving efficacy and safety for pediatric patients [9]. Group 5: Competitive Strategies in Drug Procurement - The company’s strategy in response to drug procurement policies includes prioritizing differentiated products, maintaining quality and cost advantages, and adapting to new procurement rules by shifting from a price-centric approach to a comprehensive value competition model [10].

Core Viewpoint - The Beijing Municipal Science and Technology Commission has announced the evaluation results for the 2025 Beijing Science and Technology Award, specifically the Outstanding Youth Zhongguancun Award, with candidate Wei Dongyi from Peking University being nominated [1][2]. Group 1: Award Details - The Outstanding Youth Zhongguancun Award is a category under the Beijing Science and Technology Award, established in August 2019, aimed at recognizing young scientists under 40 who have made significant discoveries or breakthroughs in scientific research [3]. - The award is evaluated annually, with a maximum of 30 recipients each year [3]. Group 2: Candidate Information - Wei Dongyi, a candidate for the award, has been involved in postdoctoral research at the Beijing International Center for Mathematical Research since December 2017 and has been an assistant professor at Peking University since December 2019 [2]. - Wei Dongyi is recognized for his contributions to the project "Mathematical Research on Flow Transition Mechanisms," which has passed the preliminary evaluation for the 2025 National Natural Science Award, with a suggested grade of second prize [2]. Group 3: Nominators - The nominators for Wei Dongyi include mathematicians and academicians Wen Lan and Wang Shisen, who are both leaders in their respective fields of differential dynamical systems and low-dimensional manifolds and geometric topology [2].

Core Viewpoint - The Beijing Municipal Education Commission has issued a reminder for parents to carefully select technology-related extracurricular training institutions, emphasizing the protection of their legal rights and the safety of prepaid funds [1]. Group 1: Selection Criteria for Training Institutions - Parents should verify the qualifications of training institutions by confirming the possession of an educational permit issued by the education administration and a business license or registration certificate from market regulation or civil affairs departments [1]. - It is essential for parents to sign standardized contracts based on the "Beijing Technology Extracurricular Training Service Contract (Sample Text) (Trial)" when enrolling and making payments [1]. Group 2: Fee Management and Compliance - Parents must refer to the "Beijing Technology Extracurricular Training Prepayment Management Measures (Trial)" to ensure the compliance of fee collection practices by training institutions [1]. - Institutions using prepaid fees cannot charge or indirectly collect fees exceeding three months or 60 class hours at once, and single payments should not exceed 5,000 yuan [1]. Group 3: Warning Against Unlawful Practices - Parents should refuse to pay any fees outside the publicly announced projects and standards, avoid forced fundraising, and reject payment through training loans [2]. - There have been reports of fraudsters impersonating the "National 12315 Platform" to issue refund announcements, prompting parents to verify such information through official channels and avoid clicking unknown links or transferring money to unfamiliar accounts [2].

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Shandong Huasu Health Care Products Co., Ltd., has obtained a utility model patent certificate from the National Intellectual Property Administration for a mouthwash filling device, which will enhance the company's intellectual property protection system and promote technological innovation [1] Group 1 - The utility model patent number is ZL 2025 20589761.9 [1] - The patent is not expected to have a significant impact on the company's recent production and operations [1] - The patent will help leverage the company's independent intellectual property advantages and foster a continuous innovation mechanism [1] Group 2 - The acquisition of the patent is aimed at improving the company's overall competitiveness [1]

备查文件 关于下属公司山东华素健康护理品公司取得实用新型专利证书的公告 共 1 页 证券代码：000931 证券简称：中关村 公告编号：2026-013 北京中关村科技发展（控股）股份有限公司 关于下属公司山东华素健康护理品公司取得实用新型 专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属 公司山东华素健康护理品有限公司取得国家知识产权局颁发的实用新型专利证 书，具体情况如下： | 实用新型名称 | | 专利申请日 | | | 授权公告日 | | | | 专利号 | | 授权公告号 | | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 一种漱口水灌 | | | | | | | | | ZL 2025 | 2 | CN | | 山东华素健康护 | | | 2025 | 年 03 | 月 | 31 日 | 2026 年 | 01 | 月 20 ...

一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 关于召开 2026 年第一次临时股东会的通知（更新后） 共 6 页 证券代码：000931 证券简称：中关村 公告编号：2026-012 北京中关村科技发展（控股）股份有限公司 关于召开 2026 年第一次临时股东会的通知（更新后） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议时间： （1）现场会议时间：2026 年 1 月 22 日 14:50 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 1 月 22 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2026 年 1 月 22 日 9:15 至 15:00 的任意时间。 ...

关于召开 2026 年第一次临时股东会的通知的补充公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2026-011 北京中关村科技发展（控股）股份有限公司 关于召开 2026 年第一次临时股东会的通知的补充公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2026 年 1 月 7 日披露了《关于召开 2026 年第一次临时股东会的通知》（公告编号： 2026-007）（以下简称：会议通知）。现对会议通知"一、召开会议的基本情 况"中"7、出席对象"的部分予以更新，具体更新内容如下： 更新前： 7、出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人。 即 2026 年 1 月 22 日下午收市时在中国结算深圳分公司登记在册的公司全 体普通股股东均有权出席股东会，并可以以书面形式委托代理人出席会议和参 加表决，该股东代理人不必是本公司股东（授权委托书模板详见附件二）。 （2）公司董事和高级管理人员。 （3）公司聘请的律师。 更新后： 7、出席对象： （1）在股权登记 ...

【#北大韦东奕入围杰出青年中关村奖#】#2位院士提名韦东奕入围#1月19日，北京市科学技术委员会、 中关村科技园区管理委员会官网发布了《2025年度北京市科学技术奖杰出青年中关村奖评审结果公示通 知》。通知称，根据《北京市科学技术奖励办法》及《北京市科学技术奖励办法实施细则》有关规定， 北京市科学技术奖人物奖评审委员会已完成2025年度北京市科学技术奖杰出青年中关村奖的评审，现对 评审结果进行公示。其中，北京大学韦东奕位列"2025年度北京市科学技术奖评审委员会评审结果目录 杰出青年中关村奖"候选人目录，提名者为文兰、王诗宬——二人均为数学家、中国科学院院士。韦东 奕1991年出生于山东济南，浙江东阳人。在山东师大附中读高中期间，他曾在第49届、50届国际数学奥 林匹克竞赛中，连续两次以满分成绩获得国际金牌。2010年，韦东奕被保送至北京大学就读，随后参与 北大"本博连读特别计划"，并于2019年毕业后留校任教。2021年5月，韦东奕接受采访时手提一瓶矿泉 水、两个馒头的形象引发网友热议。网友在了解韦东奕的数学才华和经历后，称他为"韦神"。北京大学 数学科学学院官网介绍称，韦东奕2017年12月起在北京国际数 ...

国都证券股份有限公司关于中关村股权分置改革 2025 年度保荐工作报告书 国都证券股份有限公司 关于北京中关村科技发展(控股)股份有限公司 股权分置改革 2025 年度保荐工作报告书 | 保荐机构名称 | 国都证券股份有限公司 | 二市公司证券简称 | 中关村 | | --- | --- | --- | --- | | 保荐代表人姓名 | 士品 | 上市公司证券代码 | 000931 | | 报告年度 | 2025 年度 | 报告提交时间 | 2026年1月 | 本保荐机构保证保荐工作报告书内容的真实、准确和完整，对保荐工作报告 书的虚假记载、误导性陈述或者重大遗漏负连带责任。 1、股权分置改革方案概述 中关村非流通股股东以支付股份的形式,向方案实施股权变更登记日登记在 册的全体流通股股东实施对价安排,流通股股东持有的每 10 股流通股获得 1.6 股的股份，支付对价总额为 59,975,510 股。其中:提出股权分置改革动议的非流 通股股东北京鹏泰投资有限公司、广东粤文音像实业有限公司和海源控股有限公 司合计支付对价 56,177,061 股;北京鹏泰投资有限公司为未参与提出动议的六家 非流通股股东垫付其持 ...